NCT00084292 Database for Stroke in Infants and Children: the International Pediatric Stroke Study
| NCT ID | NCT00084292 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Hospital for Sick Children |
| Condition | Cerebrovascular Accident |
| Study Type | OBSERVATIONAL |
| Enrollment | 12,000 participants |
| Start Date | 2003-01 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 12,000 participants in total. It began in 2003-01 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The International Pediatric Stroke Study (IPSS) was established in 2003 as a multi-center, multi-national clinical research registry. Over the years, it has grown to become a highly successful study vehicle for pediatric stroke research across over 100 institutions worldwide. Today, The IPSS continues to serve as the global clinical data and imaging core for multi-disciplinary pediatric experts who perform international collaborative research to better understand, prevent, and improve outcomes in pediatric stroke. The robust dataset and cohesive network enable high caliber and ground-breaking research in the field. Participating sites enroll neonates or children who have had an ischemic or hemorrhagic stroke, or may be at high risk of having a stroke. Participants have their medical and research records reviewed for information about their stroke and abstracted into a secure electronic database called REDCap, which is hosted at SickKids in Toronto Canada. The IPSS also provides an attractive imaging platform (through the Stroke Imaging Lab for Children, SILC, housed at SickKids) for sites to share clinically acquired brain images that will complement the clinical dataset. The clinical and imaging datasets will improve our understanding of the processes underlying plasticity and recovery in childhood stroke.
Eligibility Criteria
Inclusion Criteria: This registry will include all children from birth to 18 years of age who are diagnosed with stroke or a condition/disease (as defined below) that put them at high risk of stroke after Jan 1,2003 at one of the IPSS participating sites. This registry will include children diagnosed with below stroke types: * Arterial Ischemic Stroke (AIS), * Cerebral Sinovenous Thrombosis (CSVT), * AIS and CSVT * Presume Preinatal Ischemic Stroke (PPIS) * Children diagnosed with hemorrhagic stroke Children at high risk of stroke include: * Those diagnosed with arteriopathy, arteritis/vasculitis, moyamoya, dissection, sickle cell related infarcts). * Brain arteriovenous malformations Exclusion Criteria: * Premature children diagnosed with AIS. * Premature children diagnosed with PPIS * Children diagnosed with TIA (Transient Ischemic Attack) * Brain hemorrhage secondary to trauma * Refusal to provide consent for participation
Contact & Investigator
Nomazulu Dlamini, MD
PRINCIPAL INVESTIGATOR
The Hospital for Sick Children
Frequently Asked Questions
Who can join the NCT00084292 clinical trial?
This trial is open to participants of all sexes, up to 18 Years, studying Cerebrovascular Accident. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00084292 currently recruiting?
Yes, NCT00084292 is actively recruiting participants. Contact the research team at ipss.research@sickkids.ca for enrollment information.
Where is the NCT00084292 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT00084292 clinical trial?
NCT00084292 is sponsored by The Hospital for Sick Children. The principal investigator is Nomazulu Dlamini, MD at The Hospital for Sick Children. The trial plans to enroll 12,000 participants.